Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Tirzepatide Tirzepatide is a once weekly GIP (Glucose-depenent Insulinotropic Polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, representing a new class of medicines studied for the treatment of obesity
Lancet 390(10103):16641675
GHK-Cu, Acetyl Hexapeptide-8 and the hydration system support firmer, smoother skin and target fine lines and wrinkles
It comprises multiple trials targeting obesity, cardiovascular outcomes (TRIUMPH-Outcomes), and liver disease
For patients with prediabetes or insulin resistance driving weight gain and metabolic dysfunction, semaglutide addresses the glycemic component while producing weight loss that further improves insulin sensitivity a compounding metabolic benefit
The connections between obesity, systemic inflammation, and atopic dermatitis are well-established, and GLP-1 medications address several of the underlying drivers
